Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptimmune Therapeutics PLCADAP · Entity 9824 | Director | July 01, 2022 | July 01, 2022 |
| Moderna, Inc.MRNA · Entity 2025 | Chief Medical Officer | June 30, 2021 | July 02, 2021 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director | August 05, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptimmune Therapeutics PLC
Report date July 01, 2022 · Filed July 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2032-07-01 | Direct | 500,000 |
Reported balance
After 2022-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-01 · Grant · Acquired 500,000 · Balance 500,000 F1: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.
Moderna, Inc.
Report date June 30, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-06-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-06-30 · Exercise / conversion · Acquired 5,000 · Balance 5,000 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021. Row 2 · 2021-06-30 · Sale · Disposed 5,000 · Balance 0 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.93 · Expires 2030-02-28 | Direct | 121,120 |
Reported balance
After 2021-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-06-30 · Exercise / conversion · Disposed 5,000 · Balance 121,120 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021. F2: 25% of this option vested and became exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021.
F2: 25% of this option vested and became exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date August 05, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 73,247 |
Reported balance
After 2026-08-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-05 · Sale · Disposed 17 · Balance 73,247 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2020 Filed Jun 18, 2020 22:42 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 15,631 | $19.15 | $299,333.65 |
DisclosureSEC source: 0001127602-20-020083 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:42 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 24,121 | $19.15 | $461,917.15 |
DisclosureSEC source: 0001127602-20-020083 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:28 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,631 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-019353 · form4.xml · derivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,798 Underlying: Common Stock · 15,631 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:28 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,121 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-019353 · form4.xml · derivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,429 Underlying: Common Stock · 24,121 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:28 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 9,080 | $58.95 | $535,266.00 |
DisclosureSEC source: 0001127602-20-019353 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.81 to $59.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:28 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 30,672 | $58.33 | $1,789,097.76 |
DisclosureSEC source: 0001127602-20-019353 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,080 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.80 to $58.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:28 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 15,631 | $19.15 | $299,333.65 |
DisclosureSEC source: 0001127602-20-019353 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:28 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 24,121 | $19.15 | $461,917.15 |
DisclosureSEC source: 0001127602-20-019353 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 39,752 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-018880 · form4.xml · derivative · entry 11 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,550 Underlying: Common Stock · 39,752 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F9 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 47,737 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001127602-20-018880 · form4.xml · derivative · entry 10 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,243 Underlying: Common Stock · 47,737 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F8 · derivative.exercise_date: 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,467 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-018880 · form4.xml · derivative · entry 9 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,412 Underlying: Common Stock · 11,467 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F7 · derivative.exercise_date: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:15 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 4,525 | $59.81 | $270,640.25 |
DisclosureSEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 8 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.69 to $59.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:15 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 30,381 | $59.11 | $1,795,820.91 |
DisclosureSEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 7 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,525 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.67 to $59.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:15 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 48,079 | $58.13 | $2,794,832.27 |
DisclosureSEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,906 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.65 to $58.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:15 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 12,797 | $57.15 | $731,348.55 |
DisclosureSEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,985 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.61 to $57.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:15 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,174 | $56.28 | $178,632.72 |
DisclosureSEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,782 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.60 to $56.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 39,752 | $19.15 | $761,250.80 |
DisclosureSEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 47,737 | $14.22 | $678,820.14 |
DisclosureSEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 11,467 | $12.21 | $140,012.07 |
DisclosureSEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| May 26, 2020 Filed May 28, 2020 22:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 42,570 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001127602-20-018080 · form4.xml · derivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,980 Underlying: Common Stock · 42,570 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| May 26, 2020 Filed May 28, 2020 22:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 82,474 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-018080 · form4.xml · derivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,760 Underlying: Common Stock · 82,474 shares Expires 2027-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · derivative.exercise_date: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). Read SEC document |
| May 26, 2020 Filed May 28, 2020 22:05 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 125,044 | $66.54 | $8,320,427.76 |
DisclosureSEC source: 0001127602-20-018080 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| May 26, 2020 Filed May 28, 2020 22:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 82,474 | $12.21 | $1,007,007.54 |
DisclosureSEC source: 0001127602-20-018080 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| May 26, 2020 Filed May 28, 2020 22:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 42,570 | $14.22 | $605,345.40 |
DisclosureSEC source: 0001127602-20-018080 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| May 19, 2020 Filed May 20, 2020 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 112,481 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-017368 · form4.xml · derivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,234 Underlying: Common Stock · 112,481 shares Expires 2027-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). Read SEC document |
| May 19, 2020 Filed May 20, 2020 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,563 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-017368 · form4.xml · derivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,879 Underlying: Common Stock · 12,563 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| May 19, 2020 Filed May 20, 2020 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 125,044 | $78.16 | $9,773,439.04 |
DisclosureSEC source: 0001127602-20-017368 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 19, 2020 Filed May 20, 2020 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 112,481 | $12.21 | $1,373,393.01 |
DisclosureSEC source: 0001127602-20-017368 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 19, 2020 Filed May 20, 2020 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 12,563 | $12.21 | $153,394.23 |
DisclosureSEC source: 0001127602-20-017368 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 19, 2020 Filed Jun 4, 2020 22:51 UTC Amendment | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 125,044 | $78.16 | $9,773,439.04 |
DisclosureSEC source: 0001127602-20-018900 · form4a.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 125,044 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-016613 · form4.xml · derivative · entry 8 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,442 Underlying: Common Stock · 125,044 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F8 · derivative.exercise_date: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 17,744 | $62.65 | $1,111,661.60 |
DisclosureSEC source: 0001127602-20-016613 · form4.xml · nonDerivative · entry 7 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.09 to $63.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 19,817 | $63.59 | $1,260,163.03 |
DisclosureSEC source: 0001127602-20-016613 · form4.xml · nonDerivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,744 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.10 to $64.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 59,913 | $64.72 | $3,877,569.36 |
DisclosureSEC source: 0001127602-20-016613 · form4.xml · nonDerivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,561 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.11 to $65.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 25,905 | $65.46 | $1,695,741.30 |
DisclosureSEC source: 0001127602-20-016613 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,474 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.12 to $66.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,365 | $66.43 | $90,676.95 |
DisclosureSEC source: 0001127602-20-016613 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,379 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.13 to $67.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 300 | $67.23 | $20,169.00 |
DisclosureSEC source: 0001127602-20-016613 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,744 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.16 to $67.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 125,044 | $12.21 | $1,526,787.24 |
DisclosureSEC source: 0001127602-20-016613 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 05, 2020 Filed May 6, 2020 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 4,770 | $50.48 | $240,789.60 |
DisclosureSEC source: 0001127602-20-015655 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 05, 2020 Filed Jun 4, 2020 22:53 UTC Amendment | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 4,770 | $50.48 | $240,789.60 |
DisclosureSEC source: 0001127602-20-018902 · form4a.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on September 26, 2019 and January 21, 2020. Read SEC document |
| April 24, 2020 Filed Apr 27, 2020 20:12 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,000 | $47.15 | $471,500.00 |
DisclosureSEC source: 0001127602-20-014549 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,770 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 20:37 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,000 | $48.81 | $488,100.00 |
DisclosureSEC source: 0001127602-20-014136 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,770 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 13, 2020 Filed Apr 14, 2020 20:17 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,000 | $32.00 | $320,000.00 |
DisclosureSEC source: 0001127602-20-013698 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,770 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 03, 2020 Filed Apr 6, 2020 20:10 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,000 | $32.81 | $328,100.00 |
DisclosureSEC source: 0001127602-20-013315 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,770 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 27, 2020 Filed Mar 30, 2020 20:13 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,000 | $28.37 | $283,700.00 |
DisclosureSEC source: 0001127602-20-012139 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,770 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 20, 2020 Filed Mar 23, 2020 20:13 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,000 | $29.13 | $291,300.00 |
DisclosureSEC source: 0001127602-20-011751 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,770 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 20:24 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,000 | $23.00 | $230,000.00 |
DisclosureSEC source: 0001127602-20-010793 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,770 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:24 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,000 | $27.98 | $279,800.00 |
DisclosureSEC source: 0001127602-20-010107 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,770 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:35 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 28,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-009028 · form4.xml · derivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,924 Underlying: Common Stock · 28,924 shares Expires not disclosed F3 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F3 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:35 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 161,120 | $0.00 Strike: $25.93 | $0.00 |
DisclosureSEC source: 0001127602-20-009028 · form4.xml · derivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,120 Underlying: Common Stock · 161,120 shares Expires 2030-02-28 F2 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.